Prospective Clinical Drug-Drug Interaction study between Rifampicin and Fusidic Acid

Not Applicable

Recruiting

• Conditions: Medication interaction; Infection - Other infectious diseases

• Registration Number: ACTRN12619001247167
• Lead Sponsor: St Vincent's Hospital Melbourne

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2019-09-10
• Last Update Posted: 30 September 2019

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 12

Inclusion Criteria

Inpatients with presumed or confirmed staphylococcal infection
-A decision to treat with oral rifampicin and fusidic acid has already been made but not started.
-Treatment with an intravenous beta-lactam antibiotic

Exclusion Criteria

-Previous adverse reaction to rifampicin or fusidic acid
-Pregnancy
-The taking of other essential medications with a known significant interaction with rifampicin and fusidic acid
-Liver failure
-Unlikely to receive antibiotic treatment for longer than 4 weeks
-Primary intravenous treatment with vancomycin or teicoplanin
-Already on treatment with intravenous rifampicin

Study & Design

• Study Type: Observational
• Study Design: Not specified